Leocor Mining Inc. announced a 10-for-1 share consolidation effective September 18, 2026, pending approval from the Canadian Securities Exchange. This move will reduce the total number of outstanding shares to about 50 million, adjusting the exercise price and number of shares for convertible securities accordingly. Shareholders with fractional shares will have their holdings rounded up or down based on the fraction size. The company's name and trading symbol will remain unchanged, and shareholders will receive updated certificates or statements reflecting the consolidation. This consolidation aims to streamline the company's share structure as it continues its exploration projects in Eastern Canada.
Leocor Mining's upcoming share consolidation provides context for market activity. For readers following the Basic Materials sector, here is Pluang's market snapshot as of Sep 15, 2026 21:43 WIB: of 32 priced US stocks, 10 rose and 22 fell. Notable prices include Gold Fields Limited (GFI) at USD 42.57 with a 1-day change of -1.28%, Nucor Corporation (NUE) at USD 257.60 with +1.17%, and Stanley Black & Decker, Inc. (SWK) at USD 87.94 with -1.07%.
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings Inc and Omico have formed a partnership to accelerate precision oncology research in Australia by connecting cancer patients to biomarker-driven clinical trials. The collaboration combines Fortrea's expertise in oncology clinical tri...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
Fortrea Holdings Inc and Omico have formed a partnership to enhance precision oncology research in Australia by matching cancer patients with biomarker-driven clinical trials. This collaboration combines Fortrea's expertise in oncology clinical trial...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research by improving biomarker-based clinical trial planning and patient recruitment in Australia. The collaboration leverages Fortrea's clinical trial expertise a...
